A new basic-translational research paper from our Land Michael Bader's group has been published: Legchenko et al. Novel Tryptophan Hydroxylase Inhibitor TPT-001 Reverses PAH, ... (2024). JACC Basic Transl Science.
https://t.co/e7J8Xm1H3H
@3CPRCouncil@ATS_PC@PVRI@StanfordCVI
NEW PAPER published: Hysko K et al. JACC Advances (2023) - open access. Recovery of Biventricular Function After Catheter Intervention or Surgery for Neonatal Coarctation of the Aorta. https://t.co/uAwDYXvqR9
@3CPRCouncil@AEPCcongenital@StanfordCVI@BostonChildrens
New paper from @Hansmann_Lab :
HUCMSC/HUCMSC-CM has the potential to become a real game changer in the treatment of severe PAH and RV failure, by driving regeneration, mitochondrial function, autophagy and anti-inflammation.
https://t.co/zQT6UBPIgz
New paper from @Hansmann_Lab :
HUCMSC/HUCMSC-CM has the potential to become a real game changer in the treatment of severe PAH and RV failure, by driving regeneration, mitochondrial function, autophagy and anti-inflammation.
https://t.co/zQT6UBPIgz
NEW PAPER OUT:Hamberger F et al. Frontiers Cardiovasc Med, 2022. https://t.co/8rYiJShciJ
Fibrogenic signature in patients with hepatic congestion due to heart disease: PAH patients should be screened for unrecognized liver fibrosis. #WorldPHDay,#hepatology, @3CPRCouncil, @ATS_PC
NEW PAPER OUT, 02/2022:
Hansmann G et al. Even in end-stage pediatric PAH with poor RV function and low cardiac output, LuTx should be preferred over Heart-LuTx.
@3CPRCouncil, @ATS_PC, @PVRI, @PHAssociation, @PittVMI, @PhatStanford
https://t.co/rTLnanL8Gx
https://t.co/URiJBaQT6J
NEW PAPER OUT: Iablonskii P et al. JHLT, issue 2/2022
Indications and outcome after lung transplantation in children under 12 years of age: A 16-year single center experience.
https://t.co/qmli4ESTp3
@3CPRCouncil@ATS_PC@PVRI@PHAssociation@PittVMI@PhatStanford